What's in Nihon Pharmaceutical Co., Ltd's pipeline?

Nihon Pharmaceutical Co., Ltd has 11 drugs in our index: 1 marketed, 0 filed, 7 in Phase 3, 2 in Phase 2, 1 in Phase 1.

Which companies overlap with Nihon Pharmaceutical Co., Ltd's portfolio?

Top competitors by shared drug class: Boryung Pharmaceutical Co., Ltd, National Heart, Lung, and Blood Institute (NHLBI), Ahn-Gook Pharmaceuticals Co.,Ltd, Ain Shams University, Daewon Pharmaceutical Co., Ltd..

How do I subscribe to ongoing alerts?

Subscribe to /feed/company/nihon-pharmaceutical-co-ltd.xml in any RSS reader. Every regulatory action and pipeline update lands in your feed.

Last reviewed 2026-06-10 · How we verify

Nihon Pharmaceutical Co., Ltd — Portfolio Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Nihon Pharmaceutical Co., Ltd pipeline: 1 marketed, 0 filed, 7 Phase 3, 2 Phase 2. Recent regulatory actions, upcoming PDUFA, patent timeline, top competitor overlap.

1 marketed 0 filed 7 Phase 3 2 Phase 2 1 Phase 1 Live · 30-min refresh

Portfolio leaders (marketed + Phase 3 / filed)

Drug	Generic	Phase	Class	Target	Area	First approval
Suprep Bowel Prep Kit	POTASSIUM SULFATE	marketed			Gastroenterology	2010-01-01
NPB-01-ME	NPB-01-ME	phase 3
NPB-06	NPB-06	phase 3	SGLT2 inhibitor	SGLT2	Diabetes
NPB-01	NPB-01	phase 3
NPF-08 （1-day treatment）	NPF-08 （1-day treatment）	phase 3	SGLT2 inhibitor	SGLT2	Diabetes
Moviprep（1-day treatment）	Moviprep（1-day treatment）	phase 3	Osmotic laxative bowel preparation agent		Gastroenterology
NPO-11	NPO-11	phase 3	SGLT2 inhibitor	SGLT2	Diabetes
NPF-08 （2-day split dose）	NPF-08 （2-day split dose）	phase 3	ACE inhibitor	ACE	Cardiovascular

Therapeutic area mix

Diabetes · 3
Gastroenterology · 2
Cardiovascular · 1

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this portfolio.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this portfolio.

Patent timeline (forward window)

No upcoming patent expiries for this portfolio.

Competitive overlap (companies sharing drug classes)

Boryung Pharmaceutical Co., Ltd · 2 shared drug classes
National Heart, Lung, and Blood Institute (NHLBI) · 2 shared drug classes
Ahn-Gook Pharmaceuticals Co.,Ltd · 2 shared drug classes
Ain Shams University · 2 shared drug classes
Daewon Pharmaceutical Co., Ltd. · 2 shared drug classes
GlaxoSmithKline · 2 shared drug classes
Ache Laboratorios Farmaceuticos S.A. · 2 shared drug classes
Sanofi · 2 shared drug classes

Subscribe to ongoing alerts

Every new pipeline event for Nihon Pharmaceutical Co., Ltd:

Cite this brief

Drug Landscape (2026). Nihon Pharmaceutical Co., Ltd — Portfolio Competitive Intelligence Brief. https://druglandscape.com/ci/company/nihon-pharmaceutical-co-ltd. Accessed 2026-06-10.